Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Bse Healthcare
Bse Healthcare Performance
Day's Range
Low
₹50,670.32
High
₹50,904.53
52 Week Range
Low
₹40,239.45
High
₹51,574.61
| Previous Close | ₹50,764.61 |
|---|---|
| Day's Range | ₹50,670.32 - ₹50,904.53 |
| Open | ₹50,860.52 |
| 52 Week Range | ₹40,239.45 - ₹51,574.61 |
| Volume | 53,59,262 |
Bse Healthcare Companies
| Company Name | LTP (₹) | Change (₹) | Sector |
|---|---|---|---|
| Cipla Ltd. | 1434.95 |  18.95 (1.34%) |
Healthcare |
| Dr. Reddy's Laboratories Ltd. | 1175.15 | 4.15 (0.35%) |
Healthcare |
| Procter & Gamble Health Ltd. | 5836.30 | 56.55 (0.98%) |
Healthcare |
| Lupin Ltd. | 2220.25 | 0.25 (0.01%) |
Healthcare |
| Morepen Laboratories Ltd. | 93.13 | 4.70 (5.31%) |
Healthcare |
| Torrent Pharmaceuticals Ltd. | 5009.95 |  -3.05 (-0.06%) |
Healthcare |
| Abbott India Ltd. | 26175.00 | -225.00 (-0.85%) |
Healthcare |
| Glaxosmithkline Pharmaceuticals Ltd. | 3001.00 | -33.05 (-1.09%) |
Healthcare |
| Novartis India Ltd. | 1552.20 | 20.65 (1.35%) |
Trading |
| Sanofi India Ltd. | 3277.45 | 3.50 (0.11%) |
Healthcare |
| Index Name | Market Value | 52W High | 52W Low |
|---|---|---|---|
| Nifty 50 | 24201.0 | 26373.20 | 22182.55 |
| Nifty IT | 30731.05 | 40301.40 | 25699.10 |
| Nifty Next 50 | 74261.4 | 74878.45 | 59896.10 |
| NIFTY50 USD Index | 8768.3 | 10443.40 | 8132.40 |
| Nifty Bank | 57618.3 | 61764.85 | 49954.85 |
| NIFTY Midcap 100 | 63824.35 | 64139.05 | 52032.85 |
| Nifty 500 | 23520.15 | 24144.20 | 20385.65 |
| Nifty Midcap 50 | 18352.6 | 18403.50 | 14804.55 |
| Nifty 100 | 25370.1 | 26975.15 | 22720.45 |
| Nifty FMCG | 47591.3 | 58485.05 | 45334.15 |
Latest News
Glenmark Pharmaceuticals informs about media release
Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals (Glenmark) today announced the receipt of U.S. FDA approval1 for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. Glenmark’s Fluticasone Propionate Nasal Spray USP is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase®2 Nasal Spray, 0.05 mg/spray of Haleon US Holdings LLC [NDA 020121] and will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA. The company has attached media release.
The above information is a part of company’s filings submitted to BSE.
Solara Active Pharma Sciences informs about updates
Mankind Pharma informs about newspaper advertisements
In furtherance to its intimation dated August 18, 2026, with regard to the Notice of Postal Ballot of the Company and in compliance with Regulation 30 of the Listing Regulations, Mankind Pharma has informed that it enclosed copies of the newspaper advertisements published today, Wednesday, August 19, 2026, in Financial Express (English) and Jansatta (Hindi), confirming the dispatch of the Notice of Postal Ballot and providing other requisite information pursuant to the provisions of Sections 108 and 110 of the Companies Act, 2013, read with the rules made thereunder. The above information is also available on the website of the Company www.mankindpharma.com.
The above information is a part of company’s filings submitted to BSE.
NATCO Pharma submits investor presentation
Acutaas Chemicals informs about updates
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The previous close of index is ₹ as of .
The total volume of index is as of .
The percentage change in value of index is % as of .
The absolute increase in index value since the previous trading day is ₹ as of .
A stock reaching its 52-week high indicates it has attained its highest price point in the past year. This milestone may signal strong performance and positive investor sentiment. Please note that investments are subject to market risks.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
